Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

When It Comes To Its Reputation, The Pharmaceutical Industry Continues To Mess Up
Forbes
Wednesday, September 24, 2014 - 4:01pm
tags:
Physician Payment Sunshine Act, physician payments
GlaxoSmithKline set to name Philip Hampton as next chairman: report
First Word Pharma
Wednesday, September 24, 2014 - 11:26am
tags:
GSK
Zimmer and Biomet update on their mega-merger
Mass Device
Wednesday, September 24, 2014 - 11:25am
tags:
Zimmer, Biomet, M&A, devices
Acorda Rises Most Since 2011 on $525 Million Civitas Deal
Bloomberg
Wednesday, September 24, 2014 - 11:23am
tags:
Acorda, M&A, Parkinson's Disease, Civitas
Valeant offers olive branch to Allergan
Marketwatch
Wednesday, September 24, 2014 - 11:22am
tags:
Allergan, M&A, Bill Ackman, Valeant Pharmaceuticals
Anti-addiction groups call for new FDA chief
Yahoo/AP
Wednesday, September 24, 2014 - 9:49am
tags:
FDA, addiction, Margaret Hamburg
Acorda buys Civitas to gain access to Parkinson's drug
Yahoo/Reuters
Wednesday, September 24, 2014 - 9:48am
tags:
Acorda, Civitas, Parkinson's Disease, M&A, CVT-301
Lipocine testosterone therapy meets late-stage study goals
Yahoo/Reuters
Wednesday, September 24, 2014 - 9:37am
tags:
Lipocine, testosterone, LPCN 1021
FDA Fast Tracks MedImmune’s Pneumonia Drug
Drug Discovery and Development
Wednesday, September 24, 2014 - 9:03am
tags:
FDA, MedImmune, fast track, MEDI3902, AstraZeneca, nosocomial pneumonia
Biogen shoulders into gene therapy amid a second honeymoon for the field
Fierce Biotech
Wednesday, September 24, 2014 - 8:42am
tags:
Biogen Idec, gene therapy
Can copay coupons be kickbacks? HHS says yes
Fierce Pharma Marketing
Wednesday, September 24, 2014 - 8:40am
tags:
kickbacks, HHS, copay coupons
Medtronic May Be The Biggest Loser In The Tax Inversion Race After New Tax Rules By The US Treasury
Bidness Etc.
Wednesday, September 24, 2014 - 8:36am
tags:
Medtronic, tax inversions, M&A, Covidien, devices
Merrimack Does Well to License Marginal Cancer Drug to Baxter
TheStreet.com
Wednesday, September 24, 2014 - 8:30am
tags:
Merrimack Pharmaceuticals, MM-398, pancreatic cancer, Baxter International
AstraZeneca Posts Positive Data on its Type II Diabetes Drug
Yahoo/Zacks.com
Wednesday, September 24, 2014 - 8:00am
tags:
AstraZeneca, diabetes, Byetta, exenatide
Banned ImClone founder plans IPO for new venture
CNBC
Wednesday, September 24, 2014 - 7:56am
tags:
ImClone, Sam Waksal, IPOs, Kadmon
Pfizer explored takeover of rival Actavis
Marketwatch
Wednesday, September 24, 2014 - 7:54am
tags:
Pfizer, Actavis, tax inversions, M&A
Salix Receives $100 Million In Patent Infringement Settlement
Bidness Etc.
Tuesday, September 23, 2014 - 6:10pm
tags:
Salix, patents, Zegrid, Par Pharmaceutical, Santarus
Tax-deal crackdown's victims, say analysts? Mylan and Abbott, not Pfizer and AZ
Fierce Pharma
Tuesday, September 23, 2014 - 5:45pm
tags:
Mylan Labs, Pfizer, AstraZeneca, Shire, AbbVie, tax inversions, Abbott Labs
AdvaMed, PhRMA, BIO protest Sunshine law
Mass Device
Tuesday, September 23, 2014 - 5:43pm
tags:
AdvaMed, PhRMA, BIO, devices, physicial payments, Physician Payment Sunshine Act
Dealpolitik: Is Now the Time for Valeant to Make ‘Best and Final’ Offer?
WSJ Online
Tuesday, September 23, 2014 - 5:01pm
tags:
Allergan, Valeant Pharmaceuticals, M&A

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.